Evidence map›Paper›PMID 25447707›Full record

ArticleMolecular and biochemical parasitology2014

The zymogen of plasmepsin V from Plasmodium falciparum is enzymatically active.

Huogen Xiao, Brian C Bryksa, Prasenjit Bhaumik, Alla Gustchina, Yoshiaki Kiso, Shao Q Yao, Alexander Wlodawer, Rickey Y Yada

Open access · greenAbstract read
In one paragraph

Article in Molecular and biochemical parasitology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Plasmepsin V shows its carnivorous side.Nature structural & molecular biology · 2015
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 5 countries.

Huogen XiaoDepartment of Food Science, University of Guelph, 50 Stone Road East, Guelph, ON, Canada N1G2W1.
Brian C BryksaDepartment of Food Science, University of Guelph, 50 Stone Road East, Guelph, ON, Canada N1G2W1.
Prasenjit BhaumikDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai 400076, India.
Alla GustchinaProtein Structure Section, Macromolecular Crystallography Laboratory, National Cancer Institute, Frederick, MD 21702, USA.
Yoshiaki KisoLaboratory of Peptide Science, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan.
Shao Q YaoDepartment of Chemistry, National University of Singapore, 3 Science Drive, Singapore 117543, Singapore.
Alexander WlodawerProtein Structure Section, Macromolecular Crystallography Laboratory, National Cancer Institute, Frederick, MD 21702, USA.
Rickey Y YadaDepartment of Food Science, University of Guelph, 50 Stone Road East, Guelph, ON, Canada N1G2W1; Faculty of Land and Food Systems, University of British Columbia 248-2357 Main Mall Vancouver, BC V6T 1Z4. Electronic address: r.yada@ubc.ca.
National Cancer Institute · USUniversity of Guelph · CAIndian Institute of Technology Bombay · INNagahama Institute of Bio-Science and Technology · JPNational University of Singapore · SGUniversity of British Columbia · CA

Funding

Protein StructureZIABC010348 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WLODAWER, ALEXANDER · 2009 to 2025
$27.5M
Intramural NIH HHS ZIA BC010348
6 · The paper itself

Abstract

Plasmepsin V, a membrane-bound aspartic protease present in Plasmodium falciparum, is involved in the export of malaria parasite effector proteins into host erythrocytes and therefore is a potential target for antimalarial drug development. The present study reports the bacterial recombinant expression and initial characterization of zymogenic and mature plasmepsin V. A 484-residue truncated form of proplasmepsin (Glu37-Asn521) was fused to a fragment of thioredoxin and expressed as inclusion bodies. Refolding conditions were optimized and zymogen was processed into a mature form via cleavage at the Asn80-Ala81 peptide bond. Mature plasmepsin V exhibited a pH optimum of 5.5-7.0 with Km and kcat of 4.6 μM and 0.24s(-1), respectively, at pH 6.0 using the substrate DABCYL-LNKRLLHETQ-E(EDANS). Furthermore, the prosegment of proplasmepsin V was shown to be nonessential for refolding and inhibition. Unexpectedly, unprocessed proplasmepsin V was enzymatically active with slightly reduced substrate affinity (∼ 2-fold), and similar pH optimum as well as turnover compared to the mature form. Both zymogenic and mature plasmepsin V were partially inhibited by pepstatin A as well as several KNI aspartic protease inhibitors while certain metals strongly inhibited activity. Overall, the present study provides the first report on the nonessentiality of the prosegment for plasmepsin V folding and activity, and therefore, subsequent characterization of its structure-function relationships of both zymogen and mature forms in the development of novel inhibitors with potential antimalarial activities is warranted.

Indexed as

Aspartic Acid EndopeptidasesEnzyme ActivationEnzyme InhibitorsEnzyme PrecursorsPlasmodium falciparumProtein RefoldingProtozoan ProteinsRecombinant ProteinsSubstrate SpecificityAspartic Acid EndopeptidasesEnzyme InhibitorsEnzyme PrecursorsplasmepsinProtozoan ProteinsRecombinant ProteinsPlasmepsinPlasmodium falciparumProsegmentProtease inhibitorRefoldingZymogen

Identifiers

PMID25447707
PMCPMC6310130
OpenAlexW2092945615

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.